Management of relapsed and refractory Hodgkin's disease

Seminars in Radiation Oncology

Volumn 6, Issue 3, 1996, Pages 210-224

  Yahalom, J ^a  

^a Department of Radiation Oncology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL TRIAL; DRUG MEGADOSE; HODGKIN DISEASE; HUMAN; LYMPH NODE IRRADIATION; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT FAILURE;

EID: 0030017264     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-4296(96)80017-8     Document Type: Article

References (129)

1. Herman TS Hoppe RT Donaldson SS Late relapse among patients treated for Hodgkin's disease Ann Intern Med 102 1985 292 297
2. Roach MD Brophy N Cox R Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease J Clin Oncol 8 1990 623 629
3. Healey E Tarbell N Kalish L Prognostic factors for patients with Hodgkin's disease in first relapse Cancer 71 1993 2613 2620
4. Specht L Horwich A Ashley S Salvage of relapse of patients with Hodgkin's disease in clinical stages I or II who were staged with laparotomy and initially treated with radiotherapy alone. A report from the international database on Hodgkin's disease Int J Radiat Oncol Biol Phys 30 1994 805 811
5. Biti GP Cimino G Cartoni C Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I–IIA Hodgkin's disease: Eight-year update of an Italian prospective randomized study J Clin Oncol 10 1992 378 382
6. Olver IN Wolf MM Cruickshank D Nitrogen mustard, vincristine, procarbazine, and prednisolone for relapse after radiation in Hodgkin's disease: An analysis of long-term follow-up Cancer 62 1988 233 239
7. Anderson H Crowther D Deakin DP A randomised study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease: 10-year follow-up Ann Oncol 2 1991 49 54
8. Dady P McElwain T Austin D Five years' experience with Ch1VPP effective low-toxicity combination chemotherapy for Hodgkin's disease Br J Cancer 45 1982 851
9. Santoro A Viviani S Villarreal CJ Salvage chemotherapy in Hodgkin's disease irradiation failures: Superiority of doxorubicin-containing regimens over MOPP Cancer Treatment Reports 70 1986 343 348
10. Santoro A Bonadonna G Valagussa P Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's Disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy J Clin Oncol 5 1987 27 37
11. Canellos GP Anderson JR Propert KJ Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD N Engl J Med 327 1992 1478 1484
12. Longo D Young R Wesley M Twenty years of MOPP therapy for Hodgkin's disease J Clin Oncol 4 1986 1295 1306
13. Longo DL Duffey PL Young RC Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure Journal of Clinical Oncology 10 1992 210 218
14. Young RC Canellos GP Chabner BA Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy Cancer 42 1978 1001 1007
15. Frei E Luce J Gamble J Combination chemotherapy in advanced Hodgkin's disease Ann Intern Med 79 1973 376 382
16. Cimino G Biti GP Cartoni C Chemotherapy versus radiotherapy in early-stage Hodgkin's disease: evidence of a more difficult rescue for patients relapsed after chemotherapy Eur J Cancer 28A 1992 1853 1855
17. (abstr) Bonfante V Santoro A Devizzi L Outcome of patients with Hodgkin's disease relapsing after alternating MOPP/ABVD Proc Am Soc Clin Oncol 12 1993 364
18. Lohri A Barnett M Fairey RN Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: Identification of risk factors from the British Columbia experience 1970 to 1988 Blood 77 1991 2292 2298
19. Fisher R DeVita V Hubbard S Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse Ann Intern Med 90 1979 761 763
20. Viviani S Santoro A Negretti E Salvage chemotherapy in Hodgkin's disease: Results in patients relapsing more than twelve months after first complete remission Ann Oncol 1 1990 123 127
21. Santoro A Bonfante V Bonadonna G Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease Ann Intern Med 96 1982 139 143
22. (review) Buzaid AC Lippman SM Miller TP Salvage therapy of advanced Hodgkin's disease. Critical appraisal of curative potential Am J Med 83 1987 523 532
23. Straus DJ Passe S Koziner B Combination chemotherapy salvage of heavily pretreated patients with Hodgkin's disease: An analysis of prognostic factors in two chemotherapy trials and the literature Cancer Treatment Reports 65 1981 207 211
24. Harker WG Kushlan P Rosenberg SA Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe Ann Intern Med 101 1984 440 446
25. Canellos GP Petroni GR Barcos M Etoposide, vinblastine, and doxorubicin: An active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B J Clin Oncol 13 1995 2005 2011
26. (review) Canellos GP Is there an effective salvage therapy for advanced Hodgkin's disease? Ann Oncol 2 1991 1 7
27. Zinzani PL Barbieri E Bendandi M CEP regimen (CCNU, etoposide, prednimustine) for relapsed/refractory Hodgkin's disease Tumori 80 1994 438 442
28. Santoro A Viviani S Valagussa P CCNU etoposide, and prednimustine (CEP) in refractory Hodgkin's disease Semin Oncol 13 1986 23 26
29. Tseng AJ Jacobs C Coleman C Third-line chemotherapy for resistant Hodgkin's disease with Lomustine, Etoposite, and Methotrexate Cancer Treatment Reports 71 1987 475
30. Straus DJ Myers J Koziner B Combination chemotherapy for the treatment of Hodgkin's disease in relapse: Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV) Cancer Chemother Pharmacol 11 1983 80 85
31. (abstr) Tannir N Hgemeister F Vellekop L MIME: A new effective third-line chemotherapy for patients with recurrent Hodgkin's disease Proc Am Soc Clin Oncol 3 1984 245
32. Richards M Waxman J Man T EVA treatment for recurrent or unresponsive Hodgkin's disease Cancer Chemother Pharmacol 18 1986 51
33. Brusamolino E Orlandi E Canevari A Results of CAV regimen (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease Ann Oncol 5 1994 427 432
34. Brada M Eeles R Ashley S Salvage radiotherapy in recurrent Hodgkin's disease Ann Oncol 3 1992 131 135
35. Leigh BR Fox KA Mack CF Radiation therapy salvage of Hodgkin's disease following chemotherapy failure Int J Radiat Oncol Biol Phys 27 1993 855 862
36. Uematsu M Tarbell NJ Silver B Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin's disease in relapse after initial combination chemotherapy Cancer 72 1993 207 212
37. Roach MD Kapp DS Rosenberg SA Radiotherapy with curative intent: An option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease J Clin Oncol 5 1987 550 555
38. MacMillan CH Bessell EM The effectiveness of radiotherapy for localizedrelapse in patients with Hodgkin's disease (IIB-IVB) who obtained a complete response with chemotherapy alone as initial treatment Clin Oncol (R Coll Radiol) 6 1994 147 150
39. Pezner RD Lipsett JA Vora N Radical radiotherapy as salvage treatment for relapse of Hodgkin's disease initially treated by chemotherapy alone: Prognostic significance of the disease-free interval Int J Radiat Oncol Biol Phys 30 1994 965 970
40. Diehl LF Perry DJ Terebelo H Radiation as salvage therapy for patients with Hodgkin's disease relapsing after MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) chemotherapy Cancer Treatment Reports 67 1983 827 829
41. Gomez GA Kirshnamsetty RM Han T Wide-field radiation therapy plus simultaneous chemotherapy for refractory Hodgkin's disease Med Pediatr Oncol 17 1989 9 14
42. Pezner RD Nademanee A Forman SJ High-dose therapy and autologous bone marrow transplantation for Hodgkin's disease patients with relapses potentially treatable by radical radiation therapy Int J Radiat Oncol Biol Phys 33 1995 189 194
43. (review) Lohri A Connors JM Identification of risk factors in patients treated for first relapse of Hodgkin's disease Leuk Lymphoma 15 1994 189 200
44. Appelbaum FR Herzig GP Ziegler JL Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma Blood 52 1978 85 92
45. Kaizer H Levanthal B Wharam MD Cryopreserved autologous bone marrow transplantation in the treatment of selected pediatric malignancies: A preliminary report Transplant Proc 1 1979 208 211
46. Spitzer G Dicke KA Litam J High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors Cancer 45 1980 3075 3085
47. Douer D Champlin RE Ho WG High-dose combined-modality therapy and autologous bone marrow transplantation in resistant cancer Am J Med 71 1981 973 976
48. (review) Phillips GL Reece DE Connors JM Bone marrow transplantation in Hodgkin's disease Bone Marrow Transplant 10 1992 64 66
49. (review) Goldstone AH McMillan AK The place of high-dose therapy with haemopoietic stem cell transplantation in relapsed and refractory Hodgkin's disease Ann Oncol 4 1993 21 27
50. (editorial) Bierman PJ Vose JM Armitage JO Autologous transplantation for Hodgkin's disease: Coming of age? Blood 83 1994 1161 1164
51. Linch DC Winfield D Goldstone AH Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial Lancet 341 1993 1051 1054
52. Jagannath S Dicke KA Armitage JO High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease Ann Intern Med 104 1986 163 168
53. Moormeier JA Williams SF Kaminer LS Autologous bone marrow transplantation followed by involved field radiotherapy in patients with relapsed or refractory Hodgkin's disease Leuk Lymphoma 5 1991 243 246
54. Bierman PJ Bagin RG Jagannath S High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long-term follow-up in 128 patients Ann Oncol 4 1993 767 773
55. Carella AM Congiu AM Gaozza E High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: An Italian study group report J Clin Oncol 6 1988 1411 1416
56. Jagannath S Armitage JO Dicke KA Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease J Clin Oncol 7 1989 179 185
57. Philip T Dumont J Teillet F High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease Br J Cancer 53 1986 737 742
58. Reece DE Barnett MJ Connors JM Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease J Clin Oncol 9 1991 1871 1879
59. Reece DE Connors JM Spinelli JJ Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy Blood 83 1994 1193 1199
60. (review) Gulati SC Yahalom J Portlock C Autologous bone marrow transplantation Curr Probl Cancer 15 1991 1 57
61. (review) Bierman PJ Armitage JO Role of autotransplantation in Hodgkin's disease Hematol Oncol Clin North Am 7 1993 591 611
62. Carella A Carlier P Congiu A Nine years' experience with ABMT in 128 patients with Hodgkin's disease: An Italian study group report Leukemia 5 1991 68 71
63. Wheeler C Antin JH Churchill WH Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: A dose-finding study J Clin Oncol 8 1990 648 656
64. Zulian GB Selby P Milan S High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease Br J Cancer 59 1989 631 635
65. Gianni AM Siena S Bregni M Prolonged disease-free survival after high-dose sequential chemoradiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease Ann Oncol 2 1991 645 653
66. Gianni AM Siena S Bregni M High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease—a 6-year update Ann Oncol 4 1993 889 891
67. Reece D Should high risk patients with Hodgkin's disease be singled out for heavier therapeutic regimens while low risk patients are spared such therapies? Leuk Lymphoma 15 1995 19 21
68. Voillat L Deconinck E Flesch M Role of chemoresistance prior to autologous bone marrow transplantation for Hodgkin's disease Nouv Rev Fr Hematol 36 1994 423 430
69. Yahalom J Gulati SC Toia M Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease J Clin Oncol 11 1993 1062 1070
70. Yahalom J: The 10-year MSKCC experience with high-dose therapy salvage programs for Hodgkin's disease. (in press)
71. Crump M Smith AM Brandwein J High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant J Clin Oncol 11 1993 704 711
72. Colwill R Crump M Couture F Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation J Clin Oncol 13 1995 396 402
73. Chopra R McMillan AK Linch DC The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease: A single-center eight-year study of 155 patients Blood 81 1993 1137 1145
74. Phillips GL Reece DE Barnett MJ Allogeneic marrow transplantation for refractory Hodgkin's disease J Clin Oncol 7 1989 1039 1045
75. Nademanee A O'Donnell MR Snyder DS High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors Blood 85 1995 1381 1390
76. Armitage JO Bierman PJ Vose JM Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease Am J Med 91 1991 605 611
77. Reece DE Barnett MJ Shepherd JD High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV±P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy Blood 86 1995 451 456
78. Reece DE Connors JM Spinelli JJ Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy Blood 83 1994 1193 1199
79. Bennett CL Armitage JL Armitage GO Costs of care and outcomesfor high-dose therapy and autologous transplantation for lymphoid malignancies: Results from the University of Nebraska 1987 through 1991 J Clin Oncol 13 1995 969 973
80. Carella AM Carlier P Congiu A Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol Bone Marrow Transplant 8 1991 99 103
81. Carella AM Pollicardo N Pungolino E Autologous stem cell transplantation as adjuvant treatment vs no further therapy for poor-risk Hodgkin's disease in first complete remission after MOPP/ABVD Leuk Lymphoma 15 1995 59 61
82. Taylor PR Jackson GH Lennard AL Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue: The Newcastle and Northern Region Lymphoma Group Br J Cancer 67 1993 383 387
83. (review) Carella AM The place of high-dose therapy with autologous stem cell transplantation in primary treatment of Hodgkin's disease Ann Oncol 4 1993 15 19
84. Yahalom J High-dose chemotherapy and radiotherapy with bone marrow transplantation in the management of the non-Hodgkin's lymphomas Seminars in Radiation Oncology 5 1995 316 330
85. (editorial) Yahalom J Integrating radiotherapy into bone marrow transplantation programs for Hodgkin's disease Int J Radiat Oncol Biol Phys 33 1995 525 528
86. Appelbaum FR Sullivan KM Thomas ED Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease J Clin Oncol 3 1985 1490 1494
87. Butturini A Bortin MM Gale RP Graft-versus leukemia following bone marrow transplantation Bone marrow transplant 2 1987 233 242
88. Ratanatharathorn V Uberti J Karanes C Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma Blood 84 1994 1050 1055
89. Jones RJ Ambinder RF Piantadosi S Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation Blood 77 1991 649 653
90. Jones RJ Piantadosi S Mann RB High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease J Clin Oncol 8 1990 527 537
91. Lundberg JH Hansen RM Chitambar CR Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors J Clin Oncol 9 1991 1848 1859
92. Anderson JE Litzow MR Appelbaum FR Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience J Clin Oncol 11 1993 2342 2350
93. To LB Shepperd KM Haylock DN Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood Exp Hematol 18 1990 442 447
94. Kessinger A Utilization of peripheral blood stem cells in autologous transplantation Hematol Oncol Clin North Am 7 1993 535 545
95. To LB Roberts MM Haylock DN Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants Bone Marrow Transplant 9 1992 277 284
96. Liberti G Pearce R Taghipour G Comparison of peripheral blood stem-cell and autologous bone marrow transplantation for lymphoma patients: A case-controlled analysis of the EBMT Registry data. Lymphoma Working Party of the EBMT Ann Oncol 5 1994 151 153
97. Nademanee A Sniecinski I Schmidt GM High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells J Clin Oncol 12 1994 2176 2186
98. Vose JM Anderson JR Kessinger A High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma J Clin Oncol 11 1993 1846 1851
99. Sharp JG Crouse DA Marrow contamination: Detection and significance Armitage JO Antman KH High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem-Cells ed 1 1992 Williams & Wilkins Baltimore 226 248
100. Negrin RS Pesando J Detection of tumor cells in purged bone marrow and peripheral-blood mononuclear cells by polymerase chain reaction amplification of bcl-2 translocations J Clin Oncol 12 1994 1021 1027
101. (editorial) Shpall EJ Jones RB Release of tumor cells from bone marrow Blood 83 1994 623 625
102. Gulati SC Bennett CL Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease Ann Intern Med 116 1992 177 182
103. Yahalom J Gulati S Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: The Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation Ann Oncol 2 1991 67 71
104. (review) Yahalom J Re-visiting the role of radiation therapy in Hodgkin's disease Isr J Med Sci 31 1995 137 143
105. Brizel DM Winer EP Prosnitz LR Improved survival in advanced Hodgkin's disease with the use of combined modality therapy Int J Radiat Oncol Biol Phys 19 1990 535 542
106. Yahalom J Ryu J Straus DJ Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations J Clin Oncol 9 1991 2193 2201
107. Mundt AJ Sibley G Williams S Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease Int J Radiat Oncol Biol Phys 33 1995 261 270
108. Pezner RD Nademanee A Niland JC Involved-field radiation therapy for Hodgkin's disease autologous bone marrow transplantation regimens Radiother Oncol 34 1995 23 29
109. Phillips GL Wolff SN Herzig RH Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation Blood 73 1989 2086 2092
110. (review) McMillan A Goldstone A What is the value of autologous bone marrow transplantation in the treatment of relapsed or resistant Hodgkin's disease? Leuk Res 15 1991 237 243
111. Petersen FB Appelbaum FR Hill R Autologous marrow transplantation for malignant lymphoma: A report of 101 cases from Seattle J Clin Oncol 8 1990 638 847
112. (review) Phillips GL Reece DE Clinical studies of autologous bone marrow transplantation in Hodgkin's disease Baillieres Clin Haematol 15 1986 151 166
113. Yahalom J Gulati S Shank B Total lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin's disease Int J Radiat Oncol Biol Phys 17 1989 915 922
114. (review) Ahmed T Lake D Feldman E Marrow transplantation for Hodgkin's disease: Points to ponder Leuk Lymphoma 15 1995 25 26
115. Herpst JM Klein JL Leichner PK Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment J Clin Oncol 13 1995 2394 2400
116. Vriesendorp HM Herpst JM Leichner PK Polyclonal 90Yttrium labeled antiferritin for refractory Hodgkin's disease Int J Radiat Oncol Biol Phys 17 1989 815 821
117. Bierman PJ Vose JM Leichner PK Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease J Clin Oncol 11 1993 698 703
118. (review) Engert A Gottstein C Winkler U Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins Leuk Lymphoma 13 1994 441 448
119. Katsanis E Weisdorf DJ Xu Z Infusions of interleukin-1 alpha after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytolytic activity J Clin Immunol 14 1994 205 211
120. Schenkein DP Dixon P Desforges JF Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease J Clin Oncol 12 1994 2423 2431
121. Ratanatharathorn V Uberti J Karanes C Phase I study of alpha-interferon augmentation of cyclosporine-induced graft versus host disease in recipients of autologous bone marrow transplantation Bone Marrow Transplant 13 1994 625 630
122. Haim N Ben-Shahar M Epelbaum R Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide Cancer Chemother Pharmacol 36 1995 352 355
123. Szanto I Fleischmann T Eckhardt S Treatment of resistant Hodgkin's disease with CCNU, etoposide and prednimustine (CEP) Oncology 48 1991 456 458
124. Tan CT Wollner N Trippett T Pharmacologic-guided trial of sequential methotrexate and thioguanine in children with advanced malignancies J Clin Oncol 12 1994 1955 1962
125. Kaushansky K Lok S Holly RD Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin Nature 369 1994 568 571
126. Muench MO Firpo MT Moore AS Bone marrow transplantation with interleukin-1 plus kit-ligand ex-vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem-cell lineage and proliferative potential Blood 81 1993 3463 3473
127. Hagemeister FB Tannir N McLaughlin P MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease J Clin Oncol 5 1987 556 561
128. Crump M Smith AM Brandwein J High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant J Clin Oncol 11 1993 704 711
129. Horning SJ Negrin RS Chao JC Fractionated totalbody irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma J Clin Oncol 12 1994 2552 2558